Ublituximab 在复发性多发性硬化症参与者中的扩展研究
Ublituximab 在复发性多发性硬化症受试者中的开放标签扩展研究
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
研究概览
详细说明
TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS. Participants who complete the 96-week, double-blind treatment period of TG1101-RMS301 (RMS301 [NCT03277261]) or TG1101-RMS302 (RMS302 [NCT03277248]) are eligible for participation in this Open Label Extension (OLE) study. Participants may also be eligible for TG1101-RMS303 if they have completed Week 208 of TG1101-RMS201E (RMS201E [NCT03381170]) (United States of America [USA] participants only).
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Cherkasy、乌克兰、18009
- TG Therapeutics Investigational Trial Site
-
Chernihiv、乌克兰、14001
- TG Therapeutics Investigational Trial Site
-
Chernihiv、乌克兰、14029
- TG Therapeutics Investigational Trial Site
-
Chernivtsi、乌克兰、58002
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk、乌克兰、76008
- TG Therapeutics Investigational Trial Site
-
Kharkiv、乌克兰、61058
- TG Therapeutics Investigational Trial Site
-
Kharkiv、乌克兰、61103
- TG Therapeutics Investigational Trial Site
-
Kharkiv、乌克兰、61176
- TG Therapeutics Investigational Trial Site
-
Kyiv、乌克兰、03037
- TG Therapeutics Investigational Trial Site
-
Kyiv、乌克兰、03115
- TG Therapeutics Investigational Trial Site
-
Lviv、乌克兰、79000
- TG Therapeutics Investigational Trial Site
-
Lviv、乌克兰、79010
- TG Therapeutics Investigational Trial Site
-
Odesa、乌克兰、65009
- TG Therapeutics Investigational Trial Site
-
Poltava、乌克兰、36011
- TG Therapeutics Investigational Trial Site
-
Ternopil、乌克兰、46027
- TG Therapeutics Investigational Trial Site
-
Uzhhorod、乌克兰、88018
- TG Therapeutics Investigational Trial Site
-
Vinnytsia、乌克兰、21005
- TG Therapeutics Investigational Trial Site
-
Zaporizhia、乌克兰、69065
- TG Therapeutics Investigational Trial Site
-
Zaporizhia、乌克兰、96900
- TG Therapeutics Investigational Trial Site
-
Zhytomyr、乌克兰、10002
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Tbilisi、乔治亚州、00112
- TG Therapeutics Investigational Trial Site
-
Tbilisi、乔治亚州、00114
- TG Therapeutics Investigational Trial Site
-
Tbilisi、乔治亚州、00159
- TG Therapeutics Investigational Trial Site
-
Tbilisi、乔治亚州、00160
- TG Therapeutics Investigational Trial Site
-
Tbilisi、乔治亚州、00172
- TG Therapeutics Investigational Trial Site
-
Tbilisi、乔治亚州、00179
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Arkhangelsk、俄罗斯、163045
- TG Therapeutics Investigational Trial Site
-
Barnaul、俄罗斯、656045
- TG Therapeutics Investigational Trial Site
-
Bryansk、俄罗斯、241033
- TG Therapeutics Investigational Trial Site
-
Chelyabinsk、俄罗斯、454021
- TG Therapeutics Investigational Trial Site
-
Kemerovo、俄罗斯、650066
- TG Therapeutics Investigational Trial Site
-
Krasnoyarsk、俄罗斯、660037
- TG Therapeutics Investigational Trial Site
-
Kursk、俄罗斯、305007
- TG Therapeutics Investigational Trial Site
-
Moscow、俄罗斯、125367
- TG Therapeutics Investigational Trial Site
-
Moscow、俄罗斯、127015
- TG Therapeutics Investigational Trial Site
-
Nizhny Novgorod、俄罗斯、603155
- TG Therapeutics Investigational Trial Site
-
Novosibirsk、俄罗斯、630007
- TG Therapeutics Investigational Trial Site
-
Novosibirsk、俄罗斯、630087
- TG Therapeutics Investigational Trial Site
-
Pyatigorsk、俄罗斯、357538
- TG Therapeutics Investigational Trial Site
-
Saint Petersburg、俄罗斯、197002
- TG Therapeutics Investigational Trial Site
-
Saint Petersburg、俄罗斯、197110
- TG Therapeutics Investigational Trial Site
-
Saint Petersburg、俄罗斯、197376
- TG Therapeutics Investigational Trial Site
-
Saransk、俄罗斯、430032
- TG Therapeutics Investigational Trial Site
-
Smolensk、俄罗斯、214018
- TG Therapeutics Investigational Trial Site
-
Tomsk、俄罗斯、634050
- TG Therapeutics Investigational Trial Site
-
Tyumen、俄罗斯、625000
- TG Therapeutics Investigational Trial Site
-
Ufa、俄罗斯、450005
- TG Therapeutics Investigational Trial Site
-
Yekaterinburg、俄罗斯、620102
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Osijek、克罗地亚、31000
- TG Therapeutics Investigational Trial Site
-
Varaždin、克罗地亚、42000
- TG Therapeutics Investigational Trial Site
-
Zagreb、克罗地亚、10000
- TG Investigational Trial Site
-
-
-
-
-
Belgrade、塞尔维亚、11000
- TG Therapeutics Investigational Trial Site
-
Kragujevac、塞尔维亚、34000
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Katowice、波兰、40-555
- TG Therapeutics Investigational Trial Site
-
Katowice、波兰、40-568
- TG Therapeutics Investigational Trial Site
-
Katowice、波兰、40-684
- TG Therapeutics Investigational Trial Site
-
Krakow、波兰、31-505
- TG Therapeutics Investigational Trial Site
-
Lodz、波兰、41-800
- TG Therapeutics Investigational Trial Site
-
Olsztyn、波兰、10-561
- TG Therapeutics Investigational Trial Site
-
Poznan、波兰、61-583
- TG Therapeutics Investigational Trial Site
-
Warsaw、波兰、04-141
- TG Therapeutics Investigational Trial Site
-
Zabrze、波兰、04-749
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Grodno、白俄罗斯、230017
- TG Therapeutics Investigational Trial Site
-
Grodno、白俄罗斯、320017
- TG Therapeutics Investigational Trial Site
-
Minsk、白俄罗斯、220114
- TG Therapeutics Investigational Trial Site
-
Minsk、白俄罗斯、220116
- TG Therapeutics Investigational Trial Site
-
Minsk、白俄罗斯、220226
- TG Therapeutics Investigational Trial Site
-
-
-
-
California
-
Pasadena、California、美国、91105
- TG Therapeutics Investigational Trial Site
-
-
Colorado
-
Denver、Colorado、美国、80045
- TG Therapeutics Investigational Trial Site
-
-
Florida
-
Miami、Florida、美国、33136
- TG Therapeutics Investigational Trial Site
-
Tampa、Florida、美国、33612
- TG Therapeutics Investigational Trial Site
-
-
Illinois
-
Northbrook、Illinois、美国、60062
- TG Therapeutics Investigational Trial Site
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- TG Therapeutics Investigational Trial Site
-
-
Michigan
-
Detroit、Michigan、美国、48201
- TG Therapeutics Investigational Trial Site
-
-
Nevada
-
Las Vegas、Nevada、美国、89106
- TG Therapeutics Investigational Trial Site
-
-
New Jersey
-
Teaneck、New Jersey、美国、07666
- TG Therapeutics Investigational Trial Site
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87131
- TG Therapeutics Investigational Trial Site
-
-
New York
-
Amherst、New York、美国、14266
- TG Therapeutics Investigational Trial Site
-
-
Ohio
-
Columbus、Ohio、美国、43214
- TG Therapeutics Investigational Trial Site
-
Westerville、Ohio、美国、43081
- TG Therapeutics Investigational Trial Site
-
-
Tennessee
-
Knoxville、Tennessee、美国、37922
- TG Therapeutics Investigational Trial Site
-
-
Texas
-
Dallas、Texas、美国、75246
- TG Therapeutics Investigational Trial Site
-
Frisco、Texas、美国、75034
- TG Therapeutics Investigational Trial Site
-
Round Rock、Texas、美国、78681
- TG Therapeutics Investigational Trial Site
-
San Antonio、Texas、美国、78258
- TG Therapeutics Investigational Trial Site
-
-
Washington
-
Seattle、Washington、美国、98109
- TG Therapeutics Investigational Trial Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Participants must meet the following criteria:
- Complete the 96-week double-blind TG1101-RMS301 (NCT03277261) or TG1101-RMS302 (NCT03277248) study or complete the final Week 208 visit of the TG1101-RMS201E (NCT03381170) study
- Investigator believes may benefit from treatment with ublituximab
- Are able and willing to provide written informed consent (e.g., before the first infusion) and to comply with the study protocol
- Female participants of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 20 weeks after the last dose of ublituximab
Exclusion Criteria:
Participants who meet any of the following exclusion criteria are not to be enrolled to this study:
-
Any significant or uncontrolled medical condition or treatment-emergent, clinically significant laboratory abnormality such as:
- Absolute neutrophil count < 1.5 x 10e3/µL
- Hematocrit < 24%
- Platelet count < 150,000 cell/mm^3
- Hypogammaglobulinemia immunoglobulin G (IgG) < 4.0g/L
-
Active infection
-
Ongoing pregnancy (female participants)
-
Participants who discontinued ublituximab treatment or withdrew consent from the TG1101-RMS301 or TG1101-RMS302 study during the 96-week evaluation period or prior to completing the final Week 208 visit of the TG1101-RMS201E study
-
Participants who have started any disease modifying therapy (DMT), stem cell transplantation, or participation in any other interventional clinical trial after completion of the 96-week visit in the TG1101-RMS301, TG1101-RMS302, or after completing the final Week 208 visit of the TG1101-RMS201E study
-
Participants who have had a confirmed multiple sclerosis (MS) relapse within the past 30 days prior to Week 1 Day 1 (W1D1). Following a relapse, participants must be neurologically stable for at least 30 days prior to screening or W1D1 of the OLE
-
Participants with unstable disease activity
-
Presence of malignancy, except for surgically excised basal or squamous cell skin lesions
-
Vaccination with live virus within 2 months of randomization
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Ublituximab Infusions
RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study. |
Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Annualized Relapse Rate (ARR)
大体时间:Up to Week 336
|
ARR is defined as the number of relapses per-participant year. The estimate of ARR will be the total number of relapses divided by the sum of duration on study treatment (years). |
Up to Week 336
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TG1101-RMS303
- 2019-003625-16 (EudraCT编号)
- 2019 (美国 NIH 拨款/合同)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.